company background image
CLN

Celon Pharma WSE:CLN Stock Report

Last Price

zł13.00

Market Cap

zł663.4m

7D

-4.6%

1Y

-65.3%

Updated

29 Sep, 2022

Data

Company Financials +
CLN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CLN Stock Overview

Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations.

Celon Pharma S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Celon Pharma
Historical stock prices
Current Share Pricezł13.00
52 Week Highzł39.05
52 Week Lowzł12.68
Beta0.79
1 Month Change-12.99%
3 Month Change-16.45%
1 Year Change-65.33%
3 Year Change-69.30%
5 Year Change-61.54%
Change since IPO-41.65%

Recent News & Updates

Aug 04
We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth

We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

CLNPL PharmaceuticalsPL Market
7D-4.6%0.8%-7.9%
1Y-65.3%-1.8%-35.7%

Return vs Industry: CLN underperformed the Polish Pharmaceuticals industry which returned -0.4% over the past year.

Return vs Market: CLN underperformed the Polish Market which returned -33.1% over the past year.

Price Volatility

Is CLN's price volatile compared to industry and market?
CLN volatility
CLN Average Weekly Movement8.5%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement6.1%
10% most volatile stocks in PL Market11.7%
10% least volatile stocks in PL Market3.8%

Stable Share Price: CLN is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CLN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Polish stocks.

About the Company

FoundedEmployeesCEOWebsite
2002504Maciej Wieczorekhttps://www.celonpharma.com

Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders.

Celon Pharma S.A. Fundamentals Summary

How do Celon Pharma's earnings and revenue compare to its market cap?
CLN fundamental statistics
Market Capzł663.39m
Earnings (TTM)-zł17.40m
Revenue (TTM)zł191.12m

3.5x

P/S Ratio

-38.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CLN income statement (TTM)
Revenuezł191.12m
Cost of Revenuezł59.51m
Gross Profitzł131.61m
Other Expenseszł149.02m
Earnings-zł17.40m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Nov 23, 2022

Earnings per share (EPS)-0.34
Gross Margin68.86%
Net Profit Margin-9.11%
Debt/Equity Ratio0%

How did CLN perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

-78%

Payout Ratio